This last week we presented our project at CES 2019 in Las Vegas, one of the most important electronic congresses in the world. This has been thanks to the European American Enterprise Council, which has chosen us as a project with the potential to be implemented in the United States.

During these days, we have learned from new digital health projects that are coming up. In MJN we believe that technology must be at the service of people and it is in this same direction that we put all our efforts to improve the quality of life of people with epilepsy.

At the same time, we have had the opportunity to present our project to different investors and partners who will be able to help us in the near future so that our MJN-SERAS device to assess the risk of epileptic seizures can become a reality in the United States.

“We’ve had the opportunity

present our project to

different investors and partners”

One of the most important challenges is obtaining certification from the American Drug Agency, FDA, and that’s where private equity support can help us obtain FDA permits.

It should be noted that within the events organized by EAEC, the Silicon Valley Funding Summit, we won first prize in the startup competition. Forty projects from all over the world took part in the contest. We are proud that we can talk about epilepsy in all these forums and that we are also recognized as an outstanding project at the international level.

Finally, we would like to thank Acció and her representative here at the CES, Alba Quer, for their invaluable help in the day-to-day running of the congress.


Find out your risk of having an epileptic seizure at any time and place.

Leave a Reply

Abrir chat
Contacta con nosotros al momento
Chat con Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.